Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Date
The Centers for Medicare & Medicaid Services Office of Minority Health (CMS OMH) will host a Building COVID-19 Vaccine Confidence webinar on Thursday, May 13 from 12:00 PM–1:00 PM (ET).
From April 12-16, U.S. members of ASCO participated in the 2021 ASCO Advocacy Summit, where 148 advocates from 44 states and the District of Columbia held 222 virtual meetings—the most ever held during an Advocacy Summit—with Members of Congress and staff to urge action on important policies to improve access to high-quality, equitable care for people with cancer.
On April 22, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior  platinum-containing regimen. Read more. 
On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
On May 5, 2021, the Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Read more. 
ASCO is excited to announce the launch of a new project stemming from a collaboration between ASCO and the Association of Community Cancer Centers (ACCC) to address the lack of racial and ethnic diversity in cancer treatment trials. The goal of the collaboration is to develop practical strategies and solutions to increase clinical trial participation among people with cancer from racial and ethnic communities historically underrepresented in cancer treatment trials.
On Thursday, May 20 from 4:00 PM–5:00 PM (ET), the call will revolve around two related subjects: ASCO’s vision for equity, diversity, and inclusion, and our 2020 Sexual Orientation and Gender Identity (SOGI) survey to research health disparities among sexual and gender minority populations. Our presenters will be Sybil Green, JD, RPh, MHA, and Charles Kamen, PhD, MPH. Register to join us on May 20.
As COVID-19 vaccines continue rolling out across the country, the Centers for Medicare and Medicaid (CMS) is taking action to protect the health and safety of patients and providers and providing updates on the latest COVID-19 resources from the Department of Health and Human Services (HHS), the Centers for Disease Control and Preventions (CDC), and CMS.